Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

Journal of Medicinal Chemistry

Volumn 45, Issue 17, 2002, Pages 3772-3793

  Pandey, Anjali ^a   Volkots, Deborah L ^a   Seroogy, Joseph M ^a   Rose, Jack W ^a   Yu, Jin Chen ^a   Lambing, Joseph L ^a   Hutchaleelaha, Athiwat ^a   Hollenbach, Stanley J ^a   Abe, Keith ^a   Giese, Neill A ^a   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 (3 PIPERIDIN 1 YLPROPOXY)QUINAZOLIN 4 YL]PIPERAZINE 1 CARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 4 PIPERAZINYLQUINAZOLINE DERIVATIVE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CT 52923; ERLOTINIB; FLT3 LIGAND; GEFITINIB; IMATINIB; KN 1022; LAPATINIB; PELITINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CHEMICAL MODIFICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; MALE; MONKEY; NONHUMAN; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; ENZYME INHIBITORS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MACACA FASCICULARIS; MALE; MICE; MICE, NUDE; MICROSOMES, LIVER; MUTATION; PHOSPHORYLATION; PIPERAZINES; PLASMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; QUINAZOLINES; RATS; RATS, INBRED LEW; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037103166     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020143r     Document Type: Article

References (41)

1. Growth factor signaling by receptor tyrosine kinases
2. Platelet-derived growth factor receptor signals
3. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by insitu hybridization
4. Platelet-derived growth factor: Mechanism of action and possible in vivo function
5. Platelet-derived growth factor and PDGF receptor are induced in mesangial proliferative nephritis in the rat
6. Inhibition of mesangial cell proliferation and matrix expansion in glumerulonephritis in the rat by antibody to platelet-derived growth factor
7. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats
8. Oncogenic kinase signaling
9. Mastocytosis: Molecular mechanisms and clinical disease heterogeneity
10. C-kit mutations in core binding factor leukemias
11. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
12. Internal tandem duplication of the Flt3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies
13. Prognostic implication of Flt3 and N-RAS gene mutations in acute myeloid leukemia
14. Oncogenic kinas signaling
15. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
16. A new series of PDGF receptor tyrosine kinase inhibitors: 3-Substituted quinoline derivatives
17. A novel series of 4-phenoxyquinoxazolines: Potent and highly selective inhibitors of PDGF receptor autophosphorylation
18. Selective inhibition of PDGF signal transduction pathway bya PTK inhibitor of the 2-phenylaminopyrimidine class
19. Structure activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor
20. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury
21. Development of antagonists of the platelet-derived growth factor receptor family
22. Potent and selective inhibitors of PDGF receptor phosphorylation. 1. Synthesis and structure-activity relationship of a new class of quinazoline derivatives
23. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of tyrosine kinase activity of the epidermal growth factor receptor
24. The epidermal growth factor receptor and its inhibition in cancer therapy
25. Tyrosine kinase inhibitors. 15, 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
26. Induction of apoptosis and cell cycle arrest by CP-358,774, an epidermal growth factor receptor tyrosine kinase
27. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
28. Preclinical profile of PKI166: A novel and potent EGFR tyrosine kinase inhibitor for clinical development
29. Functional importance of the platelet-derived growth factor receptor extracellular immunoglobin-like domains: Identification of PDGF binding site and neutralizing monoclonal antibodies
30. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
31. Epidermal growth factor receptor tyrosine kinase: Structureactivity relationships and antitumor activity of novel quinazolines
32. Tyrosine kinase inhibitors, 17: Irreversible inhibitors of the epidermal growth factor receptor; 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions
33. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
34. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cell expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
35. TEL/PDGFβR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
36. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
37. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
38. Structural mechanism for STI571 inhibition of abelson tyrosine kinase